Novavax COVID-19 vaccine shows 90% overall efficacy in Phase 3 trial

More good news in the vaccine space

The study also shows that the vaccine is 100% effective against moderate cases of COVID-19, while also protecting against variants. A key feature of the Novavax vaccine is that it is easy to store and transport, so that may help to bolster vaccine rollouts globally once supply is made available and if it is approved especially in developing countries.

Top Brokers

Sponsored

General Risk Warning
investingLive Premium
Telegram Community
Gain Access